The U.S. FDA has approved Life Biosciences’ first-in-human trial of a cell reprogramming gene therapy intended to reverse aspects of cellular aging. The initial study will test ER‑100 in patients with glaucoma, deploying viral vectors that carry three reprogramming genes under a doxycycline‑inducible switch to limit expression. Life Biosciences — co‑founded by researchers including David Sinclair — plans to treat one eye in each participant and monitor safety closely; animal work shown by the company passed preclinical safety screens though epigenetic reprogramming has previously caused cancer in some laboratory models. The small, exploratory trial will focus on tolerability and early signals of functional effect. The approval marks a high‑profile regulatory greenlight for a controversial 'reprogramming' approach and sets a precedent for tightly controlled, mechanism‑based early trials in the rejuvenation field.